Jonathan Yen-Wen Yu Sells 18,612 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 18,612 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28. Following the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $3,758,677.56. This represents a 25.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Disc Medicine Price Performance

Shares of IRON stock opened at $70.79 on Friday. The stock has a 50 day moving average price of $68.61 and a 200 day moving average price of $71.77. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.00 and a current ratio of 24.00. The firm has a market capitalization of $2.70 billion, a P/E ratio of -10.69 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, sell-side analysts predict that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors have recently made changes to their positions in IRON. ANTIPODES PARTNERS Ltd bought a new stake in shares of Disc Medicine in the fourth quarter valued at about $33,000. Aster Capital Management DIFC Ltd bought a new position in Disc Medicine during the 3rd quarter worth about $38,000. KBC Group NV bought a new position in Disc Medicine during the 4th quarter worth about $80,000. Persistent Asset Partners Ltd purchased a new position in Disc Medicine during the 4th quarter valued at about $141,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Disc Medicine by 36.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock valued at $146,000 after purchasing an additional 490 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IRON. Truist Financial reduced their price target on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Wells Fargo & Company upped their target price on shares of Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. Morgan Stanley raised their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $105.80.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.